0001209191-21-036627.txt : 20210528 0001209191-21-036627.hdr.sgml : 20210528 20210528180255 ACCESSION NUMBER: 0001209191-21-036627 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210526 FILED AS OF DATE: 20210528 DATE AS OF CHANGE: 20210528 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEE WILLIS C CENTRAL INDEX KEY: 0001517775 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35527 FILM NUMBER: 21981978 MAIL ADDRESS: STREET 1: 20725 S. WESTERN AVE. STREET 2: SUITE 136 CITY: TORRANCE STATE: CA ZIP: 90501 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emmaus Life Sciences, Inc. CENTRAL INDEX KEY: 0000822370 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870419387 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21250 HAWTHORNE BOULEVARD, SUITE 800 CITY: TORRANCE STATE: CA ZIP: 90503 BUSINESS PHONE: 310-214-0065 MAIL ADDRESS: STREET 1: 21250 HAWTHORNE BOULEVARD, SUITE 800 CITY: TORRANCE STATE: CA ZIP: 90503 FORMER COMPANY: FORMER CONFORMED NAME: MYnd Analytics, Inc. DATE OF NAME CHANGE: 20151211 FORMER COMPANY: FORMER CONFORMED NAME: CNS RESPONSE, INC. DATE OF NAME CHANGE: 20070313 FORMER COMPANY: FORMER CONFORMED NAME: STRATIVATION, INC. DATE OF NAME CHANGE: 20051115 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-26 0 0000822370 Emmaus Life Sciences, Inc. EMMA 0001517775 LEE WILLIS C 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE CA 90503 1 1 0 0 Vice Chairman & COO Common stock, $0.001 par value 2021-05-26 4 P 0 2700 1.53 A 244774 D Common stock, $0.001 par value 2021-05-27 4 P 0 2000 1.58 A 246774 D Common stock, $0.001 par value 2021-05-28 4 P 0 3900 1.57 A 250674 D Common stock, $0.001 par value 108761 I By Fidelity Traditional IRA FBO Willis C. Lee The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.59, inclusive. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.61, inclusive. Willis C. Lee 2021-05-28